Why did Quest Diagnostics report such a large net loss in 1996?

The 1996 net loss of $626.0 million was driven primarily by a $445.0 million non-cash write-down of intangible assets, which resulted from adopting a new fair-value-based impairment policy at the Spin-Off Distribution. Additional charges included $223.6 million in restructuring and special charges, mainly for Damon-related billing settlement reserves, and $111.2 million in bad debt expense.

How did the spin-off from Corning change the company's finances?

Corning distributed the company's shares to its stockholders on December 31, 1996. The company borrowed $500 million (a $350 million term loan and $150 million of senior subordinated notes) to repay Corning, and Corning forgave or contributed the remaining intercompany debt, reducing total debt by roughly $700 million and cutting annual interest expense by about $28 million. The company expects lower interest and amortization expense in 1997.

What is Corning's indemnification covering, and what remains the company's risk?

Corning agreed to indemnify the company against monetary penalties and settlements for pending or previously settled government billing claims, including the Damon settlement and the Nichols and other government investigations, plus 50% of certain private claims above $42 million (capped at $25 million). Corning does not cover governmental claims arising from subpoenas after December 31, 1996, non-governmental claims unrelated to indemnified matters, or claims not settled by December 31, 2001. Litigation fees are also excluded. The Nichols investigation remains open, and the company's reserves of about $81 million may prove insufficient.

Will Quest Diagnostics pay dividends to shareholders?

No. The company does not expect to pay dividends on its common stock in the foreseeable future. The bank Credit Agreement prohibits cash dividends on common stock, and the indenture for the 10.75% senior subordinated notes restricts dividends based primarily on a percentage of earnings, as defined.

What are the main drivers of future profitability that management highlights?

Management cites its strategy of becoming the lowest-cost, highest-quality provider, including standardizing processes and billing and lab systems (estimated conversion cost of $55 to $85 million over several years), pursuing account profitability by repricing or dropping unprofitable managed care contracts, and reducing bad debt through improved billing and medical necessity documentation. These savings are forward-looking, with the majority expected by the end of 1998, and management also notes that continued price pressure from managed care and Medicare reimbursement cuts remains a risk.

DGX 10-K FY1996 Annual Report — Revenue, Net Income, EPS

01—Abstract

Summary

Summary of the 10-K filed March 19, 1997. Cited figures are marked; the original filing is the authoritative source.

Quest Diagnostics (DGX) reported a deeply loss-making 1996 as it emerged as an independent public company from Corning via the December 31, 1996 Spin-Off Distribution.

Net revenues were roughly flat at $1.62 billion^a (down about 0.8% from $1.63 billion), but the company posted a net loss of $626.0 million, driven primarily by a $445 million non-cash write-down of intangible assets (adopted under a new fair-value impairment policy), $223.6 million in restructuring and special charges (including $119 million Damon billing settlement-related reserves and a $13.7 million software write-off), and bad debt expense that, while reduced from 1995, remained elevated at $111 million. Adjusted EBITDA fell to $166.4 million (10.3% of revenue) from $176.5 million, with price declines of roughly 3% from managed care shifts and Medicare fee cuts. The balance sheet was substantially reshaped by the recapitalization.

Long-term debt fell to $515 million^b from $1.2 billion, following a $350 million term loan, $150 million of 10.75% senior subordinated notes, and about $862 million of capital contributed by Corning, which forgave intercompany debt and funded the Damon settlement. Stockholders' equity rebounded to $539 million from $296 million. Corning also agreed to indemnify the company for most pre-1997 government billing claims, though the company retains exposure to non-indemnified private claims and the open Nichols investigation.

Management's forward-looking commentary points to lower interest and amortization expense in 1997, improved cash flow predictability, and a goal of becoming the lowest-cost, highest-quality provider, although cost savings are targeted mainly for 1998. The company does not expect to pay dividends.

02—Key points

Key Highlights

Net loss of $626.0 million in 1996 versus a $52.1 million loss in 1995, driven mainly by a $445.0 million non-cash intangible asset write-down tied to the Spin-Off Distribution.
Net revenues of $1.616 billion, roughly flat versus $1.629 billion in 1995, with average price declines of about 3% offset by a 0.6% increase in clinical testing volume.
Adjusted EBITDA declined to $166.4 million (10.3% of revenues) from $176.5 million (10.8%), reflecting price pressure, higher wages, and severe Q1 1996 winter weather.
Long-term debt reduced to $515.0 million from $1,195.6 million after the recapitalization, which included a $350 million term loan and $150 million of 10.75% senior subordinated notes due 2006.
Stockholders' equity increased to $538.7 million from $295.8 million, primarily from $862 million of capital contributed by Corning in connection with the spin-off.
Restructuring and special charges totaled $223.6 million in 1996, including $142 million for Damon-related government claim reserves and $46 million in Q2, plus a $13.7 million billing software write-off; total reserves for claims were about $81 million.
Bad debt expense fell to $111.2 million (6.9% of revenues) from $152.6 million, although DSOs improved to 72 days, and the company's billing and managed care pricing challenges remain significant.

03—Questions

Frequently Asked Questions

Why did Quest Diagnostics report such a large net loss in 1996?
The 1996 net loss of $626.0 million was driven primarily by a $445.0 million non-cash write-down of intangible assets, which resulted from adopting a new fair-value-based impairment policy at the Spin-Off Distribution. Additional charges included $223.6 million in restructuring and special charges, mainly for Damon-related billing settlement reserves, and $111.2 million in bad debt expense.
How did the spin-off from Corning change the company's finances?
Corning distributed the company's shares to its stockholders on December 31, 1996. The company borrowed $500 million (a $350 million term loan and $150 million of senior subordinated notes) to repay Corning, and Corning forgave or contributed the remaining intercompany debt, reducing total debt by roughly $700 million and cutting annual interest expense by about $28 million. The company expects lower interest and amortization expense in 1997.
What is Corning's indemnification covering, and what remains the company's risk?
Corning agreed to indemnify the company against monetary penalties and settlements for pending or previously settled government billing claims, including the Damon settlement and the Nichols and other government investigations, plus 50% of certain private claims above $42 million (capped at $25 million). Corning does not cover governmental claims arising from subpoenas after December 31, 1996, non-governmental claims unrelated to indemnified matters, or claims not settled by December 31, 2001. Litigation fees are also excluded. The Nichols investigation remains open, and the company's reserves of about $81 million may prove insufficient.
Will Quest Diagnostics pay dividends to shareholders?
No. The company does not expect to pay dividends on its common stock in the foreseeable future. The bank Credit Agreement prohibits cash dividends on common stock, and the indenture for the 10.75% senior subordinated notes restricts dividends based primarily on a percentage of earnings, as defined.
What are the main drivers of future profitability that management highlights?
Management cites its strategy of becoming the lowest-cost, highest-quality provider, including standardizing processes and billing and lab systems (estimated conversion cost of $55 to $85 million over several years), pursuing account profitability by repricing or dropping unprofitable managed care contracts, and reducing bad debt through improved billing and medical necessity documentation. These savings are forward-looking, with the majority expected by the end of 1998, and management also notes that continued price pressure from managed care and Medicare reimbursement cuts remains a risk.

04—Continue

← View all 10-K filings